{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T07:02:57Z","timestamp":1747206177824,"version":"3.40.5"},"reference-count":0,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["COPD"],"DOI":"10.2147\/copd.s167730","type":"journal-article","created":{"date-parts":[[2018,9,2]],"date-time":"2018-09-02T20:33:32Z","timestamp":1535920412000},"page":"2707-2720","source":"Crossref","is-referenced-by-count":7,"title":["Cost-effectiveness of roflumilast as an add-on to triple inhaled therapy versus triple inhaled therapy in patients with severe and very severe COPD associated with chronic bronchitis in the UK"],"prefix":"10.2147","volume":"Volume 13","author":[{"given":"Chris","family":"Kiff","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandrine","family":"Ruiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nebibe","family":"Varol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danny","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Davies","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4623-3451","authenticated-orcid":true,"given":"Debasree","family":"Purkayastha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2018,9]]},"container-title":["International Journal of Chronic Obstructive Pulmonary Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=44090","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=44090","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,9,2]],"date-time":"2018-09-02T20:33:33Z","timestamp":1535920413000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/cost-effectiveness-of-roflumilast-as-an-add-on-to-triple-inhaled-thera-peer-reviewed-article-COPD"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":0,"URL":"https:\/\/doi.org\/10.2147\/copd.s167730","relation":{},"ISSN":["1178-2005"],"issn-type":[{"type":"electronic","value":"1178-2005"}],"subject":[],"published":{"date-parts":[[2018,9]]}}}